Larimar Therapeutics, Inc. — Q1 2022 Form 10-Q
Business context and reporting period. Clinical-stage biotechnology company developing CTI-1601, a recombinant fusion protein intended to deliver frataxin to cells in patients with Friedreich’s ataxia. This filing covers the three months ended March 31, 2022. Larimar has no approved products and has not generated revenue.
Financial results and liquidity
- Revenue and margins: No product revenue; gross margin is not applicable. No clear value for other revenue is reported.
- Operating expenses: Research and development was $5.8 million versus $9.0 million in Q1 2021; general and administrative expense was $3.1 million versus $3.1 million. Total operating expenses were $8.9 million, down $3.2 million year over year.
- Loss: Net loss was $8.9 million versus $12.1 million; basic and diluted loss per share was $0.49 versus $0.76.
- Cash flow: Operating activities used $7.5 million, compared with $11.2 million in Q1 2021. There were no investing or financing cash flows in Q1 2022. Cash, cash equivalents and restricted cash declined $7.5 million during the quarter.
- Balance sheet: Cash and cash equivalents were $62.6 million at March 31, down from $70.1 million at year-end; restricted cash was $1.3 million. Current assets were $64.9 million and current liabilities $8.9 million. Total liabilities were $14.1 million, including $5.9 million of operating lease liabilities; the filing reports no borrowings.
- Capitalization: Stockholders’ equity was $57.1 million, compared with $64.4 million at December 31, 2021. Shares outstanding were 17,710,450 at March 31 and May 10, 2022.
Material changes versus Q1 2021
Net loss narrowed by $3.1 million, primarily because R&D expense fell by $3.2 million. Management attributed the R&D decline mainly to lower clinical supply manufacturing costs ($2.2 million) and clinical trial costs ($1.9 million), partly offset by higher personnel, non-clinical, professional-fee and stock-compensation costs. Operating cash use also declined. The prior-year period included $5.3 million of net investing cash inflow from marketable debt securities; Q1 2022 had none.
Outlook, management commentary and risks
- The FDA maintained the clinical hold on the CTI-1601 program in February 2022 and requested additional data. An FDA Type C meeting was scheduled for early Q3 2022; the company said it did not know when, or if, the hold would be lifted. No interventional patient trials were enrolling or underway at the time of the hold.
- Earlier Phase 1 SAD and MAD trials showed dose-dependent increases in frataxin levels in evaluated tissues after dosing for up to 13 days, with no serious adverse events reported in those trials. The hold followed mortalities at the highest dose levels in a 26-week non-human-primate toxicology study.
- Management expected cash and cash equivalents to fund forecast operating expenses and capital requirements for at least 12 months from issuance of the financial statements. It expects continued losses and additional financing needs; the timing and terms of future funding are uncertain.
- As of May 10, 2022, approximately $29.2 million remained available under the company’s $50 million at-the-market equity program. Sales carry a 3% agent commission and could dilute existing shareholders.
- Key risks include resolving the clinical hold, obtaining satisfactory nonclinical and clinical results, manufacturing and supply execution, future financing access, and potential COVID-19 or geopolitical disruptions. The filing reports no material pending litigation and no material changes to risk factors beyond those discussed in its 2021 Form 10-K.
Important facts for investors to verify
- Updates from the FDA meeting and the specific data required to resolve the CTI-1601 clinical hold.
- Whether and when clinical development can resume, and the timing, design and cost of the next proposed trial.
- Cash runway assumptions, quarterly spending trends and the company’s plans for additional capital; track any ATM issuance and resulting dilution.
- How the toxicology-study mortalities affect the program’s safety profile and regulatory path, alongside the limited duration and scope of the reported Phase 1 results.
- Share-count reconciliation: the filing reports 17.7 million shares outstanding, while Q1 weighted-average shares were 18.3 million; it also notes 628,403 prefunded warrants and excludes 3.08 million anti-dilutive stock equivalents from diluted loss per share.